DB
Devivasha Bordoloi
The Wistar Institute, Indian Institute of Technology Guwahati
0000-0003-2513-9343
Employment
-
The Wistar Institute Post-Doctoral Fellow2019 - Present
Education
-
Indian Institute of Technology Guwahati PhD2014 - 2019
Projects & Funding
Projects & funding information is unavailable.
Publications (47)
- Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape. Save
- Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers. Save
- Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2. Save
- A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy. Save
- In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme. Save
- Loss of TIPE3 reduced the proliferation, survival and migration of lung cancer cells through inactivation of Akt/mTOR, NF-κB, and STAT-3 signaling cascades. Save
- Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases. Save
- Human tumor necrosis factor alpha-induced protein eight-like 1 exhibited potent anti-tumor effect through modulation of proliferation, survival, migration and invasion of lung cancer cells. Save
- Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens. Save
- Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing. Save